文献速递其他结缔组织病

在干燥病小鼠模型中鉴定致病性PD-1+CD8+ T细胞以实现有效的嵌合抗原受体治疗

Identification of Pathogenic PD-1+CD8+ T Cells for Effective Chimeric Antigen Receptor Therapy in a Murine Model of Sjögren Disease.
PubMed 文献 · Arthritis Rheumatol · 2025-04-30

本研究在Il12b-/-Il2ra-/-小鼠模型及干燥病患者样本中,通过单细胞RNA测序和流式细胞术鉴定出PD-1+CD8+ T细胞为克隆扩增且活化的致病性CD8+ T细胞,其数量与患者疾病活动度正相关;PD-1靶向CAR-T细胞治疗可显著缓解模型小鼠的干燥病症状。

要点

  • PD-1是干燥病唾液腺和外周组织中克隆扩增且活化的致病性CD8+ T细胞的综合标志物。
  • 干燥病患者唇腺中PD-1+CD8+ T细胞数量与疾病活动度正相关。
  • PD-1靶向CAR-T细胞治疗在干燥病模型小鼠中显著缓解症状。

核心结论

  • 在干燥病患者和鼠模型中鉴定出PD-1+CD8+ T细胞的致病作用。
  • PD-1靶向CAR-T细胞治疗在干燥病模型小鼠中显示出疗效。
  • 研究结果为开发干燥病患者临床治疗策略提供了有前景的途径。

研究设计与样本

  • 采用Il12b-/-Il2ra-/-小鼠作为原发性胆汁性胆管炎与干燥病重叠的小鼠模型。
  • 对干燥病患者和相关鼠模型样本进行单细胞RNA测序和流式细胞术分析以鉴定致病性CD8+ T细胞。
  • 进行共享T细胞受体分析以追溯致病性CD8+ T细胞的潜在前体。
  • 通过评估鼠模型的唾液腺分泌功能、免疫学特征和组织病理学改变来评价PD-1靶向CAR-T细胞治疗的疗效。

主要发现

  • PD-1被鉴定为干燥病唾液腺和外周组织中克隆扩增且活化的致病性CD8+ T细胞的综合标志物。
  • 流式细胞术证实干燥病患者唾液腺中PD-1+CD8+ T细胞的活化表型和细胞毒性。
  • 干燥病患者唇腺中PD-1+CD8+ T细胞数量与疾病活动度正相关。
  • PD-1靶向CAR-T细胞治疗在鼠模型中显著缓解干燥病症状。

临床怎么用

  • 作者认为研究结果提示PD-1+CD8+ T细胞耗竭在干燥病中具有治疗潜力。
  • 作者认为PD-1靶向CAR-T细胞治疗为干燥病患者临床治疗策略的开发提供了有前景的途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Activated T cells play a pivotal pathogenic role in the progression of Sjögren disease (SjD); however, there are currently no targeted therapies specifically designed to address them. This study aims to identify pathogenic CD8+ T cells in SjD and develop targeted therapeutic strategies. METHODS: Il12b-/-Il2ra-/- mice, a murine model for overlapping primary biliary cholangitis and SjD, were employed in this study. Pathogenic CD8+ T cells were identified through single-cell RNA sequencing and flow cytometry analyses of samples from both patients with SjD and relevant murine models. Shared T cell receptor analysis was conducted to trace the potential precursors of pathogenic CD8+ T cells. The efficacy of PD-1-targeted chimeric antigen receptor (CAR)-T cell therapy was evaluated through the assessment of salivary gland secretory function, immunologic profiles, and histopathological changes in the murine model. RESULTS: We identified PD-1 as a comprehensive marker of clonally expanded and activated pathogenic CD8+ T cells in the salivary glands and peripheral tissues. Flow cytometry further confirmed the activation phenotype and cytotoxicity of PD-1+CD8+ T cells in the salivary glands of patients with SjD. Notably, the number of PD-1+CD8+ T cells in the labial glands positively correlated with disease activity in patients with SjD. These findings highlight the therapeutic potential of depleting PD-1+CD8+ T cells in SjD. Furthermore, PD-1-targeted CAR-T cell therapy significantly alleviated SjD symptoms in a murine model. CONCLUSION: We identified the pathogenic role of PD-1+CD8+ T cells in both patients with SjD and a murine model and demonstrated the efficacy of PD-1-targeted CAR-T cell therapy in SjD model mice. Our findings suggest a promising avenue for developing clinical therapeutic strategies for patients with SjD.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ma JF, Xu T, Zhu HX, et al. Identification of Pathogenic PD-1+CD8+ T Cells for Effective Chimeric Antigen Receptor Therapy in a Murine Model of Sjögren Disease. Arthritis Rheumatol. 2025. PMID: 40026078. doi:10.1002/art.43144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。